臨床検査54巻6号

2010年06月発行

今月の主題 注目されるサイトカイン 各論

骨代謝とサイトカイン

著者： 高柳広¹²

所属機関： ¹東京医科歯科大学大学院分子情報伝達学 ²科学技術振興機構ERATO

ページ範囲：P.651 - P.658

　骨と免疫系は，骨髄微小環境をはじめ，サイトカイン・受容体・転写因子などの制御分子を共有し，緊密な関係にある．関節リウマチにおける炎症性骨破壊の研究は，T細胞と破骨細胞の相互作用におけるサイトカイン制御の重要性に光を当てた．破骨細胞は破骨細胞分子化因子RANKLや炎症性サイトカインを介した正の制御とともに，インターフェロンによる負の制御を受けており，複雑なサイトカインネットワークの制御下にある．免疫細胞でのサイトカイン産生制御の鍵を握る転写因子NFATは，破骨細胞の運命決定因子としても機能する．このような研究から，骨と免疫の相互作用や共通メカニズムを解析する骨免疫学が発展し，様々な疾患の制御に重要な知見を提供するようになってきた．

参考文献

1) Takayanagi H：Osteoimmunology：shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol　7：292-304, 2007

2) Yasuda H, Shima N, Nakagawa N, et al：Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA　95：3597-3602, 1998

3) Lacey DL, Timms E, Tan HL, et al：Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell　93：165-176, 1998

4) Wong BR, Rho J, Arron J, et al：TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem　272：25190-25194, 1997

5) Arron JR, Choi Y：Bone versus immune system. Nature　408：535-536, 2000

6) Theill LE, Boyle WJ, Penninger JM：RANK-L and RANK：T cells, bone loss, and mammalian evolution. Annu Rev Immunol　20：795-823, 2002

7) Feldmann M, Maini RN：Anti-TNF α therapy of rheumatoid arthritis：what have we learned? Annu Rev Immunol　19：163-196, 2001

8) Takayanagi H, Ogasawara K, Hida S, et al：T cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ. Nature　408：600-605, 2000

9) Takayanagi H, Kim S, Matsuo K, et al：RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature　416：744-749, 2002

10) Takayanagi H, Kim S, Koga T, et al：Induction and activation of the transcription factor NFATc1(NFAT2)integrate RANKL signaling for terminal differentiation of osteoclasts. Dev Cell　3：889-901, 2002

11) Takayanagi H：Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol　5：667-676, 2009

12) Firestein GS, Manning AM：Signal transduction and transcription factors in rheumatic disease. Arthritis Rheum　42：609-621, 1999

13) Pettit AR, Ji H, von Stechow D, et al：TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol　159：1689-1699, 2001

14) Redlich K, Hayer S, Ricci R, et al：Osteoclasts are essential for TNF-α-mediated joint destruction. J Clin Invest　110：1419-1427, 2002

15) Takayanagi H, Juji T, Miyazaki T, et al：Suppression of arthritic bone destruction by adenovirus-mediated csk gene transfer to synoviocytes and osteoclasts. J Clin Invest　104：137-146, 1999

16) Kong YY, Feige U, Sarosi I, et al：Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature　402：304-309, 1999

17) Boyle WJ, Simonet WS, Lacey DL：Osteoclast differentiation and activation. Nature　423：337-342, 2003

18) Suda T, Takahashi N, Udagawa N, et al：Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocrine Rev　20：345-357, 1999

19) Anderson DM, Maraskovsky E, Billingsley WL, et al：A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature　390：175-179, 1997

20) Lomaga MA, Yeh WC, Sarosi I, et al：TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev　13：1015-1024, 1999

21) Naito A, Azuma S, Tanaka S, et al：Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells　4：353-362, 1999

22) Asagiri M, Takayanagi H：The molecular understanding of osteoclast differentiation. Bone　40：251-264, 2006

23) Koga T, Inui M, Inoue K, et al：Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature　428：758-763, 2004

24) Azuma Y, Kaji K, Katogi R, et al：Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem　275：4858-4864, 2000

25) Kobayashi K, Takahashi N, Jimi E, et al：Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med　191：275-286, 2000

26) Lam J, Takeshita S, Barker JE, et al：TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest　106：1481-1488, 2000

27) Takayanagi H, Oda H, Yamamoto S, et al：A new mechanism of bone destruction in rheumatoid arthritis：synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun　240：279-286, 1997

28) Takayanagi H, Iizuka H, Juji T, et al：Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum　43：259-269, 2000